INDV vs NVST
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INDV presents a stark contrast between severe balance sheet fragility and explosive operational growth. While the Piotroski F-Score of 2/9 and a negative Price/Book ratio indicate significant financial health risks and potential insolvency concerns, these are offset by a massive 376.20% YoY earnings growth and a highly attractive forward P/E of 10.03. The stock is currently trading at a significant discount to its growth-based intrinsic value of $48.38, supported by a 'strong_buy' analyst consensus.
NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.
Compare Another Pair
Related Comparisons
INDV vs NVST: Head-to-Head Comparison
This page compares Indivior Pharmaceuticals, Inc. (INDV) and Envista Holdings Corporation (NVST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.